Monk and Herzog Hammer Out PARP Nuances in Ovarian Cancer

Season 4 Episode 41  ·  Mar 18, 2021, 09:27 PM
Headliner
Share
Subscribe

In our exclusive interview, Monk and Herzog discussed the importance of molecular testing in ovarian cancer and the utility of PARP inhibitor maintenance and treatment.

Share
Subscribe
Next
Borgen Breaks Down the Domino Effect of Expanded Education and Banished Stigmas in Male Breast Cancer
Top episodes
DeNunzio Describes the Advantages of Proton Beam Therapy in Oncology
by OncLive® On Air
FDA Approval Insights: Amivantamab and Mobocertinib in EGFR Exon 20 Insertion+ NSCLC
by OncLive® On Air
Milhem Talks Mechanism of Action, Delivery Methodology, and Ongoing Trials With RP1
by OncLive® On Air